Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 30 of 30 results for thalidomide

  1. Carfilzomib for previously treated multiple myeloma (TA657)

    Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA657

  2. Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)

    Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA380

  3. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA322

  4. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

    Technology appraisal guidance
    Published
    24 September 2025

    Sections for TA1098

  5. Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

    autologous stem cell transplantation. These studies were performed before thalidomide, bortezomib and lenalidomide were used as myeloma...

    Research recommendation
    Published
    5 April 2016

  6. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    23 October 2007
    View recommendations

    Sections for TA129

  7. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

    Technology appraisal guidance
    Published
    14 December 2011
    View recommendations

    Sections for TA238

  8. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA658

  9. Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

    Evidence-based recommendations on momelotinib (Omjjara) for treating myelofibrosis-related splenomegaly or symptoms in adults.

    Technology appraisal guidance
    Published
    20 March 2024
    View recommendations

    Sections for TA957

  10. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

    Technology appraisal guidance
    Published
    6 June 2023
    View recommendations

    Sections for TA897

  11. Dupilumab for treating moderate to severe prurigo nodularis (TA955)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.

    Technology appraisal guidance
    Published
    13 March 2024
    View recommendations

    Sections for TA955

  12. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  13. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

    NICE guideline
    Last updated
    13 August 2019
    View recommendations

    Sections for NG89

  14. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development Reference number: GID-TA10568 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Past appeals and decisions

    Past technology appraisal appeals and decisions